Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Zentalis Pharmaceuticals, Inc. (ZNTL : NSDQ)
 
 • Company Description   
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK.

Number of Employees: 177

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.41 Daily Weekly Monthly
20 Day Moving Average: 1,155,285 shares
Shares Outstanding: 46.63 (millions)
Market Capitalization: $1,044.97 (millions)
Beta: 2.72
52 Week High: $87.19
52 Week Low: $17.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.49% 8.96%
12 Week -56.33% -50.92%
Year To Date -73.34% -67.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1359 BROADWAY SUITE 1710
-
NEW YORK,NY 10018
USA
ph: 212-433-3791
fax: -
info@zentalis.com None
 
 • General Corporate Information   
Officers
Anthony Y. Sun - Chief Executive Officer; Executive Chairman and Pr
Kevin D. Bunker - Chief Operating Officer
Melissa B. Epperly - Chief Financial Officer and Treasurer
Cam S. Gallagher - Director
Karan S. Takhar - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98943L107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 46.63
Most Recent Split Date: (:1)
Beta: 2.72
Market Capitalization: $1,044.97 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.12 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.24
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -5.65%
vs. Previous Quarter: -18.02%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -50.81
12/31/21 - -48.89
09/30/21 - -47.01
ROA
03/31/22 - -42.53
12/31/21 - -42.27
09/30/21 - -42.17
Current Ratio
03/31/22 - 6.93
12/31/21 - 7.98
09/30/21 - 9.58
Quick Ratio
03/31/22 - 6.93
12/31/21 - 7.98
09/30/21 - 9.58
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.91
12/31/21 - 8.05
09/30/21 - 8.75
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©